{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:39Z","timestamp":1782452799656,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trifluridine\/Tipiracil (FTD\/TPI) combined with bevacizumab (Bev) is a standard treatment for patients with unresectable metastatic colorectal cancer (mCRC) in later-line therapy. Despite the availability of other drugs like regorafenib and fruquintinib, there is no consensus on the optimal treatment choice or sequence for later-line therapies due to a lack of clearly defined prognostic indicators. This multicenter real-world analysis aimed to identify predictive factors related to the effectiveness of FTD\/TPI\u2009+\u2009Bev.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the medical records from our institution and collaborating centers of 71 mCRC patients given FTD\/TPI\u2009+\u2009Bev as third-line or later treatment. Survival data were calculated using the Kaplan\u2013Meier method, and group comparisons were made using the log-rank test. Multivariate analyses of progression-free survival (PFS) and overall survival (OS) were performed using a Cox proportional-hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A performance status (PS) of 0\u20131, absence of liver metastases, and fewer metastatic sites were significantly associated with improved PFS. For OS, significant differences were observed according to PS, presence of liver metastases, number of metastatic sites, and\n                      <jats:italic>RAS\/BRAF<\/jats:italic>\n                      mutational status. Among patients who received anti-VEGF agents in second-line therapy, those with a second-line PFS of more than 9\u00a0months had significantly better median PFS and OS with FTD\/TPI\u2009+\u2009Bev compared to those with a median PFS of 9\u00a0months or less. In multivariate analysis, PS and duration of second-line PFS were the only significant predictors of PFS and OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The response to anti-VEGF agents in second-line therapy may predict the efficacy of FTD\/TPI\u2009+\u2009Bev in subsequent treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03035-w","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:03:32Z","timestamp":1777572212000},"page":"1267-1274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prior response to anti-VEGF agents predicts the efficacy of trifluridine\/tipiracil plus bevacizumab in patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-3522","authenticated-orcid":false,"given":"Masahiro","family":"Hirakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Okagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohichi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"3035_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"3035_CR2","unstructured":"Adam M, Chang GJ, Chen Y-J, et al (2025) NCCN guidelines version 1.2025 Colon Cancer Continue NCCN Guidelines Panel Disclosures"},{"key":"3035_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol 34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"key":"3035_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22","volume":"41","author":"VK Morris","year":"2022","unstructured":"Morris VK, Kennedy EB, Baxter NN et al (2022) Treatment of metastatic colorectal cancer: ASCO Guideline. J Clin Oncol 41:678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22","journal-title":"J Clin Oncol"},{"key":"3035_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/nejmoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919. https:\/\/doi.org\/10.1056\/nejmoa1414325","journal-title":"N Engl J Med"},{"key":"3035_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/nejmoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M et al (2023) Trifluridine\u2013Tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657\u20131667. https:\/\/doi.org\/10.1056\/nejmoa2214963","journal-title":"N Engl J Med"},{"key":"3035_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"key":"3035_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R et al (2023) Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402:41\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(23)00772-9","journal-title":"Lancet"},{"key":"3035_CR9","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Li\u00e8vre","year":"2006","unstructured":"Li\u00e8vre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992\u20133995. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0191","journal-title":"Cancer Res"},{"key":"3035_CR10","doi-asserted-by":"crossref","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, et al (2008) K-ras mutations and benefit from Cetuximab in advanced colorectal cancer","DOI":"10.1056\/NEJMoa0804385"},{"key":"3035_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/nejmoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard J-Y, Oliner KS, Siena S et al (2013) Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023\u20131034. https:\/\/doi.org\/10.1056\/nejmoa1305275","journal-title":"N Engl J Med"},{"key":"3035_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02240-8","author":"J van de Haar","year":"2023","unstructured":"van de Haar J, Ma X, Ooft SN et al (2023) Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer. Nat Med. https:\/\/doi.org\/10.1038\/s41591-023-02240-8","journal-title":"Nat Med"},{"key":"3035_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO","volume":"36","author":"J Xu","year":"2017","unstructured":"Xu J, Kim W, Shen L et al (2017) Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol 36:350\u2013358. https:\/\/doi.org\/10.1200\/JCO","journal-title":"J Clin Oncol"},{"key":"3035_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled Phase 2 trial. Lancet Oncol 13:993\u20131001. https:\/\/doi.org\/10.1016\/S1470-2045(12)70345-5","journal-title":"Lancet Oncol"},{"key":"3035_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100511","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Van Cutsem E, Li J et al (2022) Effect of KRAS codon 12 or 13 mutations on survival with Trifluridine\/Tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100511","journal-title":"ESMO Open"},{"key":"3035_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102945","author":"J Tabernero","year":"2024","unstructured":"Tabernero J, Taieb J, Fakih M et al (2024) Impact of KRASG12 mutations on survival with Trifluridine\/Tipiracil plus Bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the Phase III SUNLIGHT trial. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102945","journal-title":"ESMO Open"},{"key":"3035_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102064","author":"B Doleschal","year":"2023","unstructured":"Doleschal B, Taghizadeh H, Lentner T et al (2023) Bevacizumab mitigates codon-specific effects of Trifluridine\/Tipiracil on efficacy outcome parameters in metastatic colorectal cancer. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102064","journal-title":"ESMO Open"},{"key":"3035_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04798-2","volume":"40","author":"Y Omori","year":"2025","unstructured":"Omori Y, Matsukuma S, Kawa M et al (2025) Prognostic impact and risk factors of severe neutropenia in the early phase of treatment with Trifluridine-Tipiracil for metastatic colorectal cancer patients: a single-center retrospective study. Int J Colorectal Dis 40:11. https:\/\/doi.org\/10.1007\/s00384-024-04798-2","journal-title":"Int J Colorectal Dis"},{"key":"3035_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13370-8","author":"T Takahashi","year":"2025","unstructured":"Takahashi T, Shigeyasu K, Kondo Y et al (2025) Predictive marker for response to trifluridine\/tipiracil plus bevacizumab in metastatic colorectal cancer patients. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-024-13370-8","journal-title":"BMC Cancer"},{"key":"3035_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03907-z","author":"G Soler","year":"2025","unstructured":"Soler G, Gr\u00e1valos C, Rivera F et al (2025) Predictive factors of efficacy for FTD\/TPI plus Bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT Phase III trial. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-025-03907-z","journal-title":"Clin Transl Oncol"},{"key":"3035_CR21","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.1016\/j.annonc.2023.09.1804","volume":"34","author":"G Prager","year":"2023","unstructured":"Prager G, Taieb J, Fakih M et al (2023) 613P effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the Phase III SUNLIGHT trial. Ann Oncol 34:S439\u2013S440. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1804","journal-title":"Ann Oncol"},{"key":"3035_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of Bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol 14:29\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(12)70477-1","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03035-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:02:37Z","timestamp":1782450157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03035-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3035"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03035-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kohichi Takada has received lecture fees from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, Sanofi, MSD K.K., Takeda Pharmaceutical Company Limited, Zeria Pharmaceutical Co., Ltd., and Sysmex Corporation, unrelated to this study. Other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}